| | | Firm | Analyst | | Argus Research Company | John Eade | | Atlantic Equities | Richard J. Purkiss, PhD | | Bank of America Merrill Lynch | Rachel McMinn | | Barclays | C. Anthony Butler | | BMO Capital Markets | Jim Birchenough | | Brean Murray, Carret & Co. | Brian Skorney, CFA | | Citigroup | Yaron Werber, MD | | Cowen & Company | Phil Nadeau, PhD | | Credit Suisse | Ravi Mehrotra, PhD | | Deutsche Bank | Robyn Karnauskas | | First Global Stockbroking Ltd. | Kavita Thomas | | Goldman Sachs | Sapna Srivastava | | ISI | Mark Schoenebaum | | Jefferies & Company | Thomas Wei | | JPMorgan | Geoffrey Meacham, PhD | | Lazard | William Tanner | | Leerink | Steve Y. Yoo | | Morgan Stanley | Marshall Urist | | Morningstar | Karen Andersen, CFA | | Needham | Alan Carr | | Oppenheimer | Bret Holley, PhD | | Piper Jaffray | M. Ian Somaiya | | RBC Capital Markets | Michael Yee | | Robert W. Baird & Co | Thomas J. Russo, CFA | | Sanford C. Bernstein & Co. | Geoffrey Porges, PhD | | Standard and Poors | Steven Silver | | Stifel Nicolaus | Joel Sendek | | Summer Street Research Partners | Carol Werther | | Think Equity | Marko Kozul | | UBS | Matthew Roden, PhD | | Wells Fargo | Brian Abrahams | | William Blair & Company | John Sonnier |
|
 |
| Gilead Sciences is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Gilead Sciences's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Gilead Sciences or its management. Gilead Sciences does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. |
|
